Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Oncology to specialised palliative home care systematic transition: the Domus randomised trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. eHealth-mind the gap

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient-reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL.

METHODS: BC patients in chemo- or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ-C30 and QLQ-BLM30 and 45 selected PRO-CTCAE items. Spearman's correlation analysis was performed for all PRO-CTCAE items and QLQ-C30 global QoL and subdomains.

RESULTS: In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO-CTCAE items and the expected domain of QoL. The PRO-CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (rs = -0.603, P < .0001), concentration (S, severity item) and cognitive function (rs = -0.704, P < .0001), discouraged (F) and emotional function (rs = -0.659, P < .0001), fatigue (S) and role function (rs = -0.659, P < .0001) and sad (F) and emotional function (rs = -0.711, P < .0001). The weakest correlations were found for the PRO-CTCAE items urinary frequency, incontinence and urge, all with variations in the direction and significance of the correlations.

CONCLUSIONS: This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients.

OriginalsprogEngelsk
TidsskriftCancer Medicine
Vol/bind9
Udgave nummer9
Sider (fra-til)3078-3087
Antal sider10
ISSN2045-7634
DOI
StatusUdgivet - maj 2020

Bibliografisk note

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

ID: 60921488